Deprivation of arginine by recombinant human arginase in prostate cancer cells

@inproceedings{Hsueh2012DeprivationOA,
  title={Deprivation of arginine by recombinant human arginase in prostate cancer cells},
  author={Eddy C Hsueh and Stephanie M Knebel and Wai-hung Lo and Yun-Chung Leung and Paul Ning-Man Cheng and Chung-Tsen Hsueh},
  booktitle={Journal of Hematology & Oncology},
  year={2012}
}
BackgroundRecombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant anti-proliferative activity in cancer cells deficient in the expression of ornithine carbamoyl transferase (OCT). Interestingly, a variety of cancer cells such as melanoma and prostate cancer deficient in argininosuccinate synthetase (ASS) are sensitive to arginine deprivation by… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

Combined use of arginase and dichloroacetate exhibits anti‐proliferative effects in triple negative breast cancer cells

VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

VIEW 2 EXCERPTS

Cell death.

Arginine deprivation as a targeted therapy for cancer.

VIEW 2 EXCERPTS

Arginine metabolism: boundaries of our knowledge.

VIEW 2 EXCERPTS